ES
Evan Seigerman BMO Capital Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
30
Avg Return
Past Year
Past Year
6.4%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
66.7%
Neutral
23.8%
Negative
9.5%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Mega Cap
Over $200B
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
Drug Manufacturers - Specialty & Generic
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Outperform
Maintained
| $100 |
45%
upside
| 2 | +18% |
0
%
| 17 Feb ‘26 3 months ago |
|
|
|
Market Perform
Maintained
| $140 |
11%
downside
| 2 | – |
–
| 12 Feb ‘26 3 months ago |
|
|
|
Market Perform
Maintained
| $196 |
5%
upside
| 1 | -22% |
–
| 9 Feb ‘26 3 months ago |
|
|
|
Outperform
Upgraded
| $130 |
12%
upside
| 1 | +17% |
0
%
| 18 Dec ‘25 5 months ago |
|
|
|
Outperform
Maintained
| $54 |
2%
upside
| 3 | +52% |
0
%
| 9 Dec ‘25 5 months ago |
|
|
|
Outperform
Maintained
| $850 |
42%
upside
| 4 | +8.6% |
0
%
| 4 Dec ‘25 6 months ago |
|
|
|
Outperform
Maintained
| $1,200 |
12%
upside
| 2 | +3.7% |
0
%
| 4 Dec ‘25 6 months ago |
|
|
|
Outperform
Maintained
| $372 |
14%
upside
| 1 | +8.4% |
0
%
| 3 Dec ‘25 6 months ago |
|
|
|
Market Perform
Maintained
| $46 |
7%
upside
| 3 | -26% |
–
| 25 Nov ‘25 6 months ago |
|
|
|
Market Perform
Upgraded
| $11 |
27%
upside
| 2 | -246% |
0
%
| 3 Nov ‘25 7 months ago |
|
|
|
Outperform
Maintained
| $240 |
13%
upside
| 1 | +0.79% |
0
%
| 12 Sep ‘25 8 months ago |
|
|
|
Outperform
Maintained
| $530 |
24%
upside
| 1 | -1.3% |
0
%
| 5 Aug ‘25 10 months ago |
|
|
|
Underperform
Maintained
| $60 |
36%
downside
| 1 | -20% |
0
%
| 30 Jul ‘25 10 months ago |
|
|
|
Outperform
Maintained
| $26 |
2%
downside
| 2 | +4.6% |
0
%
| 12 Jun ‘25 11 months ago |
|